Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Aviragen Therapeutics downgraded to Neutral at H.C. Wainwright — Complete failure of SPIRITUS leaves little visibility to value (0.67)H.C. Wainwright downgrades AVIR to Neutral from Buy. After market close, on February 13, Aviragen announced that the Phase 2b SPIRITUS trial of its lead drug candidate, vapendavir, missed its primary and several secondary endpoints. In a very confusing result for firm, the outsized placebo effect was so large that not only did it do better than either active drug arm, but it also represents 2.2x the magnitude of the placebo effect observed in the prior RHINO study (0.44), as measured by the similar ACQ-5 scoring tool. Furthermore, firm had expected the placebo response in SPIRITUS to be less than observed in RHINO, not more, given the substantially more severe (so called enriched) patient population of SPIRITUS.</td> </tr></table>"